|
1
|
Chughtai B, Forde JC, Thomas DD, Laor L,
Hossack T, Woo HH, Te AE and Kaplan SA: Benign prostatic
hyperplasia. Nat Rev Dis Primers. 2:160312016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Egan KB: The epidemiology of benign
prostatic hyperplasia associated with lower urinary tract symptoms:
Prevalence and incident rates. Urol Clin North Am. 43:289–297.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee YJ, Lee JW, Park J, Seo SI, Chung JI,
Yoo TK and Son H: Nationwide incidence and treatment pattern of
benign prostatic hyperplasia in Korea. Investig Clin Urol.
57:424–430. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim EH, Larson JA and Andriole GL:
Management of benign prostatic hyperplasia. Annu Rev Med.
67:137–151. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lim KB: Epidemiology of clinical benign
prostatic hyperplasia. Asian J Urol. 4:148–151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Al-Khalil S, Boothe D, Durdin T, Sunkara
S, Watkins P, Yang S, Haynes A and de Riese W: Interactions between
benign prostatic hyperplasia (BPH) and prostate cancer in large
prostates: A retrospective data review. Int Urol Nephrol. 48:91–97.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khazaei S, Rezaeian S, Ayubi E,
Gholamaliee B, Pishkuhi MA, Khazaei S, Mansori K, Nematollahi S,
Sani M and Hanis SM: Global prostate cancer incidence and mortality
rates according to the human development index. Asian Pac J Cancer
Prev. 17:3793–3796. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Corona G, Tirabassi G, Santi D, Maseroli
E, Gacci M, Dicuio M, Sforza A, Mannucci E and Maggi M: Sexual
dysfunction in subjects treated with inhibitors of 5α-reductase for
benign prostatic hyperplasia: A comprehensive review and
meta-analysis. Andrology. 5:671–678. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang L, Wu B, Zha Z, Zhao H, Yuan J,
Jiang Y and Yang W: Surgical margin status and its impact on
prostate cancer prognosis after radical prostatectomy: A
meta-analysis. World J Urol. 36:1803–1815. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Macey MR and Raynor MC: Diagnosis of
benign prostatic hyperplasia. Chapter 2. Prostatic Artery
Embolization. Isaacson AJ, Bagla S, Raynor MC and Yu H: Springer;
Cham: pp. 11–19. 2020, View Article : Google Scholar
|
|
11
|
He YC, Shen Y, Cao Y, Tang FQ, Tian DF,
Huang CF, Tao H, Zhou FL, Zhang B, Song L, et al: Overexpression of
AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Cancer Biomark. 16:127–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang YY, Qi LN, Zhong JH, Qin HG, Ye JZ,
Lu SD, Ma L, Xiang BD, Li LQ and You XM: High expression of AKR1B10
predicts low risk of early tumor recurrence in patients with
hepatitis B virus-related hepatocellular carcinoma. Sci Rep.
7:421992017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reddy KA, Kumar PU, Srinivasulu M, Triveni
B, Sharada K, Ismail A and Reddy GB: Overexpression and enhanced
specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in
human breast cancers. Breast. 31:137–143. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nishinaka T, Miura T, Shimizu K and Terada
T: Identification and characterization of functional antioxidant
response elements in the promoter of the aldo-keto reductase
AKR1B10 gene. Chem Biol Interact. 276:160–166. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Khan S, Bennit HF and Wall NR: The
emerging role of exosomes in survivin secretion. Histol
Histopathol. 30:43–50. 2015.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ishola IO, Yemitan KO, Afolayan OO,
Anunobi CC and Durojaiye TE: Potential of Moringa oleifera
in the treatment of benign prostate hyperplasia: Role of
antioxidant defence systems. Med Princ Pract. 27:15–22. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao Z, Zhou B, Chen X, Huang D, Zhang X,
Wang Z, Huang H, Wang Y and Cao D: Statil suppresses cancer cell
growth and proliferation by the inhibition of tumor marker AKR1B10.
Anticancer Drugs. 25:930–937. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yao HB, Xu Y, Chen LG, Guan TP, Ma YY, He
XJ, Xia YJ, Tao HQ and Shao QS: AKR1B10, a good prognostic
indicator in gastric cancer. Eur J Surg Oncol. 40:318–324. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ko HH, Cheng SL, Lee JJ, Chen HM, Kuo MY
and Cheng SJ: Expression of AKR1B10 as an independent marker for
poor prognosis in human oral squamous cell carcinoma. Head Neck.
39:1327–1332. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hung JJ, Yeh YC and Hsu WH: Prognostic
significance of AKR1B10 in patients with resected lung
adenocarcinoma. Thorac Cancer. 9:1492–1499. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sinreih M, Štupar S, Čemažar L, Verdenik
I, Frković Grazio S, Smrkolj Š and Rižner TL: STAR and AKR1B10 are
down-regulated in high-grade endometrial cancer. J Steroid Biochem
Mol Biol. 171:43–53. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Taskoparan B, Seza EG, Demirkol S, Tuncer
S, Stefek M, Gure AO and Banerjee S: Opposing roles of the
aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer. Cell
Oncol (Dordr). 40:563–578. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Preston MA, Batista JL, Wilson KM,
Carlsson SV, Gerke T, Sjoberg DD, Dahl DM, Sesso HD, Feldman AS,
Gann PH, et al: Baseline prostate-specific antigen levels in
midlife predict lethal prostate cancer. J Clin Oncol. 34:2705–2711.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Filella X and Foj L: Prostate cancer
detection and prognosis: From prostate specific antigen (PSA) to
exosomal biomarkers. Int J Mol Sci. 17:17842016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang L, Zhang Q, Li L, Wang Z, Ying J,
Fan Y, He Q, Lv T, Han W, Li J, et al: DLEC1, a 3p tumor
suppressor, represses NF-κB signaling and is methylated in prostate
cancer. J Mol Med (Berl). 93:691–701. 2015. View Article : Google Scholar : PubMed/NCBI
|
